After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK By Investing.com
After-hours movers: Super Micro Computer (SMCI) rose ~20% on a bullish preliminary Q4 FY2026 update, with gross margins at 15% to 17% and new orders above $60B. Oklo (OKLO) and X-Energy (XE) gained on reports of a $200M federal program for nuclear power for AI data centers. Pegasystems (PEGA) fell on Q2 EPS and revenue misses. Celldex (CLDX) dropped after a Phase 2 trial failed endpoints. Alaska Air Group (ALK) slid on a weaker Q3 outlook.
How this was made
The 30-second read
Why it matters
The article provides concrete, time-sensitive datapoints (preliminary margins and orders, consensus EPS/revenue misses, clinical endpoint failure and trial discontinuation, and explicit guidance ranges) that can drive immediate repricing and near-term trading volatility.
Market read
Traders can act on same-session repricing drivers across semis, nuclear development, enterprise software, biotech pipeline risk, and airline earnings outlook.
What to watch
For SMCI, preliminary margins and orders may reverse if mix assumptions change; for PEGA and ALK, the market may focus more on forward guidance and cost trajectory than the single quarter miss.
Background
This is an after-hours multi-stock mover wrap driven by company-specific catalysts: preliminary results for SMCI, reported DOE program participation for OKLO and XE, earnings miss for PEGA, Phase 2 failure for CLDX, and a guidance gap for ALK.
Ticker impact
SMCI shares jumped after a bullish preliminary Q4 update, including gross margin expansion to 15% to 17% and new orders above $60B.
Likely continued after-hours and next-session strength, with volatility elevated around any follow-up details.
The article cites specific preliminary financial metrics (margins, orders) and a large same-day move, which typically sustains short-term repricing until the full report.
OKLO rose on reports it is joining a $200M federal program to accelerate nuclear reactor development for AI data centers.
Potential follow-through higher, but likely headline-driven volatility until official DOE details are released.
The catalyst is concrete ($200M program) but the article also notes official details are expected later, leaving execution and scope uncertainty.
X-Energy surged alongside OKLO on reports of joining the same $200M federal program for AI data-center nuclear power.
Near-term upside bias with high volatility around confirmation and program terms.
The move is tied to a specific program size, but the lack of official details in the text limits conviction on magnitude and timing.
PEGA fell after Q2 results missed consensus, with EPS $0.35 vs $0.43 and revenue $420.72M vs $427.38M.
Likely continued weakness or underperformance until guidance or commentary offsets the miss.
The article provides explicit miss figures versus consensus, which is a direct driver of after-hours repricing.
CLDX dropped after its Phase 2 barzolvolimab study in prurigo nodularis failed primary and secondary endpoints.
Further downside risk possible as investors reassess pipeline value and timelines.
The text states endpoint failure and trial discontinuation, which typically leads to immediate repricing of probability-weighted outcomes.
ALK slid after issuing a weaker near-term outlook, guiding Q3 EPS of $0.00 to $1.00 versus $1.48 consensus.
Likely continued selling pressure into the next earnings/guidance checkpoints.
The article includes a specific guidance range and a clear consensus gap, a direct driver of valuation changes.
Market effects
Chip rebound read-through supports SMCI and may lift broader server/AI infrastructure sentiment; nuclear program headlines can buoy the small-cap nuclear development complex.
US after-hours moves likely influence next-session positioning across growth and speculative healthcare/energy-adjacent names.
AI power-supply narrative links US federal support to global data-center buildout expectations, though details remain pending.
Counterpoint
Federal program headlines for OKLO and XE may be less impactful than implied until official terms, milestones, and funding disbursement schedules are confirmed.
Key entities
- companySuper Micro Computer
Preliminary Q4 update cited with gross margin expansion and new orders above $60B.
- companyOklo
Reported to join a $200M federal program for nuclear reactor development for AI data centers.
- companyX-Energy
Reported to join the same $200M federal program for AI data-center nuclear power.
- companyPegasystems
Q2 EPS and revenue missed consensus, leading to a sharp after-hours drop.
- companyCelldex Therapeutics
Phase 2 barzolvolimab trial in prurigo nodularis failed endpoints and the PN trial will be discontinued.
